Celsion Corporation Provides Business Update
HEAT Study Analysis Shows ThermoDox® Improves Progression Free Survival (PFS)
and Overall Survival (OS) when Heating is Optimized
Cash Conservation Program Facilitates the Company's Strategic Options
Engagement of Financial Advisor Assists in Evaluation of Acquisition
LAWRENCEVILLE, N.J., April 23, 2013
LAWRENCEVILLE, N.J., April 23, 2013 /PRNewswire/ --Celsion Corporation
(NASDAQ: CLSN) today is providing a business update, including the latest
findings from its analysis of clinical trial results for ThermoDox®, Celsion's
proprietary heat-activated liposomal encapsulation of doxorubicin. Celsion is
evaluating ThermoDox® in a Phase III clinical trial for primary liver cancer
(the HEAT Study), a Phase II clinical trial for colorectal liver metastasis
and a Phase II clinical trial for recurrent chest wall breast cancer.
Phase III HEAT Study Data Analysis
The Company has conducted a comprehensive analysis of the data from the Phase
III HEAT Study with key principal investigators, data experts and liver cancer
experts. This follows the announcement on January 31, 2013, that ThermoDox®
in combination with radiofrequency ablation (RFA) did not meet the study's
primary endpoint. Emerging data from the HEAT Study post analysis
demonstrates that ThermoDox® markedly improves progression free survival (PFS)
and overall survival (OS) in patients who had optimal RFA.The analysis
indicates that if patients' lesions undergo RFA for 45 minutes or more, they
clearly benefitted from ThermoDox®. These findings apply to HCC lesions from
both size cohorts of the HEAT Study (3-5 cm and 5-7 cm) and represent a
sizable subgroup of patients. This data is subject to further verification
and review by the HEAT Study Steering Committee.
"We have completed a thorough review of the HEAT Study and there is clear
evidence that ThermoDox® can benefit patients when RFA is optimized," said Dr.
Nicholas Borys, Celsion's Vice President and Chief Medical Officer. "These
data are very exciting and consistent with the mechanism of ThermoDox®
Michael Tardugno, Celsion's Chief Executive Officer, added, "Based on the
strength of these findings, the Company will request a meeting with regulatory
authorities for guidance on moving forward with our HCC development program.
We plan to disclose the details of the HEAT Study data at upcoming medical
meetings and in a peer-reviewed publication. We will provide updates on these
activities when appropriate."
The Company implemented a restructuring program to lower its operating costs
to conserve capital. The program includes elimination of approximately
one-third of Celsion's workforce and the deferral of expenses associated with
the Company's Phase II study of ThermoDox^® in combination with RFA for the
treatment of colorectal liver metastases (The ABLATE Study). Celsion expects
these measures to remain in effect until such time as it finalizes its plans
for the continuation of its development program with ThermoDox® in HCC.
Celsion ended the first quarter of 2013 with approximately $46 million in cash
and investments. Ongoing salary costs, net of restructuring costs, are
expected to reduce overall operating expenses during the current fiscal year.
"While it is difficult to eliminate positions in our talented and dedicated
workforce, this move is necessary to ensure that our costs are adequately
aligned with our resources and business strategy," Mr. Tardugno said. "We are
reducing expenses in all areas, but we are doing this with an eye toward
limiting the impact on our future development programs for ThermoDox® as well
as afford us the opportunity to identify and develop new product candidates."
Engagement of Financial Advisor to Evaluate Acquisition Alternatives
The Company has engaged Cantor Fitzgerald & Co. to conduct a comprehensive
review of merger and acquisition opportunities with the goal of identifying
novel products with high potential, or companies, for Celsion to acquire.
Strategic alternatives the Company may pursue could include, but are not
limited to, continuing its current operating plan, partnering or other
collaboration agreements, acquisition of another company's business or assets,
or a merger or other strategic transaction. There can be no assurance that
the exploration of strategic alternatives will result in any agreements or
transactions, or that, if completed, any agreements or transactions will be
successful or on attractive terms. The Company does not intend to disclose
developments with respect to this process except as required under applicable
About Celsion Corporation
Celsion is dedicated to the development and commercialization of innovative
cancer drugs, including tumor-targeting treatments using focused heat energy
in combination with heat-activated liposomal drug technology. Celsion has
research, license or commercialization agreements with leading institutions,
including the National Institutes of Health, Duke University Medical Center,
University of Hong Kong, the University of Pisa, the UCLA Department of
Medicine, the Kyungpook National University Hospital, the Beijing Cancer
Hospital and the University of Oxford. For more information on Celsion, visit
our website: http://www.celsion.com.
Celsion wishes to inform readers that forward-looking statements in this
release are made pursuant to the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. Readers are cautioned that such
forward-looking statements involve risks and uncertainties including, without
limitation, unforeseen changes in the course of research and development
activities and in clinical trials; the significant expense, time, and risk of
failure of conducting clinical trials; HEAT Study data is subject to further
verification and review by the HEAT Study Data Management Committee; the need
for Celsion to evaluate its future development plans; termination of the
Technology Development Contract or collaboration between Celsion and HISUN at
any time; possible acquisitions or licenses of other technologies, assets or
businesses or the possible failure to make such acquisitions or licenses;
possible actions by customers, suppliers, competitors, regulatory authorities;
and other risks detailed from time to time in the Celsion 's periodic reports
and prospectuses filed with the Securities and Exchange Commission. Celsion
assumes no obligation to update or supplement forward-looking statements that
become untrue because of subsequent events, new information or otherwise.
Jeffrey W. Church
Sr. Vice President – Corporate
Strategy and Investor Relations
SOURCE Celsion Corporation
Press spacebar to pause and continue. Press esc to stop.